Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-12-16-Speech-2-272"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20031216.6.2-272"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Mr President, I wish to thank the rapporteurs. The pharmaceutical review is important for EU citizens. In this review we are not only encouraging research and innovation but we are also trying to get generic medicines on to the market more quickly. This will cost the taxpayer less. Considering that the drugs bill in the UK has gone up in the region of 30% in the last three years, it is no wonder that a sensible pharmaceutical compromise is necessary. We have a compromise package on offer: either Parliament accepts a compromise or we go into a conciliation process in which we risk losing much of what Parliament has wanted.
I urge colleagues to back the compromise on offer. As one of the movers of the original amendments, I warmly welcome the introduction of Braille on the information packaging that patients receive. Product names will appear in Braille form on the packaging and a full information text will be available in a range of formats, including Braille, on request. I would have preferred more, but I accept the compromise as a step in the right direction in giving access to information to blind and partially sighted people. This is a balanced piece of legislation and one which I feel happy to support. I hope that colleagues will support the compromise."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples